Ashish Kacholia recent bets

Morgan Stanley recent bets

Recent Big Buys

Top deal-making stocks

Most insider traded stocks

Leading investors

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

The Nifty Pharma index closed 0.33 per cent at 22229.30.

Stock market update: Nifty Pharma index 0.33%

Gland Pharma shares rose after receiving FDA approval for phytonadione injectable emulsion, a product used for coagulation disorders. Despite a 15.7% YoY decline in Q2 FY25 net profit, revenue increased by 2.4%. The stock has a target price of Rs 1,813, with a ‘Hold’ rating from analysts. Technically, the stocks RSI stands at 51.5.

Gland Pharma shares rise 5% on receiving US FDA approval for vitamin K deficiency injectable

The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.

HSBC bullish on Indian pharma stocks for 2025

The Nifty Pharma index closed 0.05 per cent at 22302.60.

Stock market update: Nifty Pharma index 0.05%

The Nifty Pharma index was trading 0.4 per cent at 22380.15.

Stock market update: Nifty Pharma index 0.4% in an upbeat market

Sorbh Gupta, Senior Fund Manager at Bajaj Finserv AMC, expresses optimism about consumption trends and the pharmaceutical industry. He sees value in large-cap stocks, particularly in consumption-related companies, due to attractive valuations and anticipated cyclical improvement. Despite market volatility, Gupta remains bullish on pharma, including CDMOs and US generics, while maintaining a cautious stance on IT and industrials.

Sorbh Gupta continues to be bullish on consumer & pharma stocks. Here’s why

The Nifty Pharma index closed 0.08 per cent at 22291.45.

Stock market update: Nifty Pharma index 0.08%

In Nifty Healthcare, which was up 0.2% at 10:00 a.m., Glenmark Pharma, Syngene International, and Apollo Hospitals were among the top gainers.

Nifty Pharma, Healthcare Snap Two-Day Fall Post Jefferies’ Outlook

The Nifty Pharma index was trading 0.04 per cent at 22317.65.

Stock market update: Nifty Pharma index 0.04% in an upbeat market

Shares of Syngene International dropped 5.7%, Piramal Pharma fell 4.2%, Lauras Labs and Neuland Laboratories declined 3% and Divi’s Laboratories fell 2.8% on Monday. The BSE 500 was down 0.1%.

Pharma stocks catch a cold as US softens stance on Biosecure Act

Stocks including Wipro, Paytm, RITES, Welspun Corp, CEAT, Biocon, JSW Energy, Suven Pharma, NLC India, Linc, Delta Corp and more will be in the spotlight on Monday, December 09.

Stocks in news: Wipro, Paytm, RITES, Welspun Corp, CEAT, Biocon, JSW Energy & Suven Pharma

The ETF tracks Nifty Pharma Index which is designed to reflect the behavior and performance of the pharmaceutical sector in India.